US2003211115A1PendingUtilityA1

Adjuvant compositions for mucosal and injection delivered vaccines

53
Priority: Jun 19, 2001Filed: May 8, 2003Published: Nov 13, 2003
Est. expiryJun 19, 2021(expired)· nominal 20-yr term from priority
Inventors:Jay D. Gerber
A61P 37/04A61P 43/00A61K 2039/541A61K 39/245A61K 39/12A61K 2039/543A61K 2039/5254A61K 2039/542A61K 2039/55511A61K 2039/545A61K 2039/55555A61K 39/39C12N 2710/16734A61P 1/04
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An adjuvant for vaccines comprising lecithin and a non-acrylic polymer selected from among polyvinyl acetate phthalate, cellulose acetate phthalate, methylcellulose, polyvinyl alcohol, and polyoxyethylene.

Claims

exact text as granted — not AI-modified
What is claimed:  
     
         1 . A composition comprising a vaccine antigen and an adjuvant wherein the adjuvant comprises lecithin and a non-acrylic polymer selected from the group consisting of polyvinyl acetate phthalate, cellulose acetate phthalate, methylcellulose, polyvinyl alcohol, polyoxyethylene and polyoxypropylene.  
     
     
         2 . The composition of  claim 1  wherein the concentrations of the lecithin and the polymer in the composition are each about 0.0001-10% by weight.  
     
     
         3 . The composition of  claim 2  wherein the concentration of the lecithin and the polymer in the composition are each about 0.001-1.0% by weight.  
     
     
         4 . The composition of  claim 1  wherein the vaccine antigen comprises a killed or attenuated substance selected from the group consisting of bacterial, viral, parasitic, DNA and structural subunits of these organisms.  
     
     
         5 . The composition of  claim 1  further comprising a substance selected from one or more of the group consisting of preservatives, surfactants, and probiotics.  
     
     
         6 . The composition of  claim 1  further including one or more minor ingredients in a concentration ranging from about 0.001-1.0% by weight.  
     
     
         7 . The composition of  claim 1  further comprising a cross linker to link the antigen to the adjuvant.  
     
     
         8 . The composition of  claim 7  wherein the cross-linker comprises a compound selected from the group consisting of glutaraldehyde, carbodiimide, mixed anhydride, and bisdiazotized benzidene.  
     
     
         9 . The composition of  claim 1  further including an adjuvant selected from the group consisting of saponins, fractions of saponins, synthesized fractions of saponins, ISCOMS, pluronic polyols, muramyl dipeptide and analogues thereof, trehalose dimyoclate, lipopolysaccharide derivatives, and cytokines.  
     
     
         10 . The composition of  claim 9  wherein the adjuvant is present in a concentration up to about 10% by weight of the composition.  
     
     
         11 . The composition of  claim 1  that is lyophilized.  
     
     
         12 . A composition comprising a adjuvant comprising lecithin and a non-acrylic polymer selected from the group consisting of polyvinyl acetate phthalate, cellulose acetate phthalate, methylcellulose, polyvinyl alcohol, and polyoxyethylene.  
     
     
         13 . The composition of  claim 12  further comprising an antigen.  
     
     
         14 . The composition of  claim 12  wherein the concentrations of the lecithin and the polymer in the composition are each about 0.0001-10% by weight.  
     
     
         15 . The composition of  claim 14  wherein the concentration of the lecithin and the polymer in the composition are each about 0.001-1.0% by weight.  
     
     
         16 . The composition of  claim 12  wherein the vaccine antigen comprises a killed or attenuated substance selected from the group consisting of bacterial, viral, parasitic, DNA and structural subunits of these organisms.  
     
     
         17 . The composition of  claim 12  further comprising a substance selected from one or more of the group consisting of preservatives, surfactants, and probiotics.  
     
     
         18 . The composition of  claim 12  further including one or more minor ingredients in a concentration ranging from about 0.001-1.0% by weight.  
     
     
         19 . The composition of  claim 13  further comprising a cross linker to link the antigen to the adjuvant.  
     
     
         20 . The composition of  claim 19  wherein the cross-linker comprises a compound selected from the group consisting of glutaraldehyde, carbodiimide, mixed anhydride, and bisdiazotized benzidene.  
     
     
         21 . The composition of  claim 12  further including an adjuvant selected from the group consisting of saponins, fractions of saponins, synthesized fractions of saponins, ISCOMS, pluronic polyols, muramyl dipeptide and analogues thereof, trehalose dimyoclate, lipopolysaccharide derivatives, and cytokines.  
     
     
         22 . The composition of  claim 21  wherein the adjuvant is present in a concentration up to about 10% by weight of the composition.  
     
     
         23 . The composition of  claim 12  that is lyophilized.

Join the waitlist — get patent alerts

Track US2003211115A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.